T he immune system can potentially play a protective role in malignancy; however, the vast majority of malignancies arise in immunocompetent hosts. Therefore, it would appear that tumor cells have evolved mechanisms to escape host defenses, perhaps through the evolution of successively less immunogenic clones. Cell surface major histocompatibility complex (MHC) molecules present peptides derived from processed proteins to the immune system. 1 Activation of cytotoxic T lymphocytes (CTLs) in the face of peptides derived from tumor-associated antigens (Ags) (TAA) depends upon the presence of MHC class I molecules. 2 Deficient expression of the latter limits the ability of tumor Ags presented to cytotoxic T cells. Many murine and human tumors do show a marked reduction of cell surface expression of MHC class I Ags. 3, 4 Furthermore, the suppression of MHC class I Ags has been correlated with reduced immunogenicity in syngeneic recipients and consequently with increased tumorigenicity. Although the introduction of syngeneic MHC class I genes increases the immunogenicity of many experimental tumors, this is not always sufficient to prevent local tumor growth. [5] [6] [7] The introduction of allogeneic MHC class I genes usually results in a more significant loss of tumorigenicity, indicating that the allogeneic MHCrestricted response to the TAA peptides is usually much stronger than the syngeneic one. 8, 9 Nabel and colleagues were the first to report the use of the direct transfer of allogeneic MHC class I gene into mouse tumors in vivo by retroviral vector and DNA liposome complexes. 10 They further reported its application in clinical trials on five melanoma patients: none of these patients developed complications, and the tumor actually regressed completely in one patient. 11 To date, this approach has still produced mixed results, with some recent apparent successes and failures, as outlined below. In a recent report, the direct transfer of an allogeneic MHC class I gene into tumors by biolistic transformation demonstrated complete tumor regression in all five mouse tumors. 12 In some other reports, however, the expression of allogeneic MHC class I Ag is still not sufficiently immunogenic to significantly reduce tumorigenicity. reaction may not be strong enough to completely inhibit some tumor growth. Because the cell-mediated xenograft reactions are usually as great or greater than the corresponding allogeneic responses, 16 this prompted us to use the more immunogenic MHC class I gene of xenogeneic origin for the transduction of tumor cells. Recently, Hock et al 17 reported that the transfer of xenogeneic MHC class II genes resulted in stronger immune responses than that of allogeneic MHC class II genes. This was shown by the complete loss of tumorigenicity and the induction of protective immunity against a subsequent challenge by parental tumor cells. Furthermore, the transfer of xenogeneic MHC class II genes also eliminated microscopic pre-established tumors. 17 Recently, recombinant adenoviral vectors have been used to transfer various genes into mammalian cells. These vectors have several biologic characteristics that can make them more effective for somatic cancer gene therapy than retroviral vectors and DNA/liposome complexes. These characteristics include: (a) a broad host/ cell range, (b) high levels of gene expression, (c) the ability to infect both dividing and nondividing cells, and (d) little possibility of insertion mutation of the host gene, a risk that may be increased when retroviral vectors are used, because the gene insertion by adenoviral transfer is episomal. Therefore, adenoviral vectors are being used extensively to transfer various genes such as thymidine kinase genes, tumor suppressor genes, and cytokine genes in cancer gene therapy. 18 -20 In this study, we sought to determine (a) whether the expression of more immunogenic MHC class I Ags of xenogeneic origin would lead to a more significant reduction of tumorigenicity, and (b) whether the adenovirus-mediated transfer of xenogeneic MHC class I gene would result in tumor inhibition in vivo.
MATERIALS AND METHODS

Antibodies (Abs), cells, and animals
Mouse monoclonal anti-H-2K
b Ab AF6-88 (immunoglobulin G (IgG)) and anti-H-2K d Ab SF1-1.1 (IgG) were obtained from PharMingen (San Diego, Calif). The mouse-anti-rat MHC class I Ab OX18 (IgG) was obtained from Dr. Sun (University of Alabama, Birmingham, Ala). The fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG Ab was purchased from Bio/Can Scientific (Missassauga, Ontario, Canada). The Cytoscreen immunoassay kits of interleukin-4 (IL-4), IL-10, and interferon-␥ (IFN-␥) were obtained Biosource (Camarillo, Calif). MCA-26 is a colonic adenocarcinoma cell line of the BALB/c mouse that was obtained from Dr. Cohen (Veterans Affairs Medical Center, Buffalo, NY). LN-4 is a highly metastatic mammalian carcinoma cell line from the Fisher 344 rat. 21 LMCR is a colonic carcinoma cell line from the BDIX rat. 22 These three cell lines were all maintained in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal calf sera (FCS). A human embryonic kidney cell line, 293, transfected with AdV5 E1 was obtained from Microbix Biosystems (Toronto, Ontario, Canada). This cell line was maintained in Eagle's minimum essential medium plus 10% FCS. Female BALB/c mice (4 -6 weeks old) were obtained from a colony bred at the Animal Resource Center of the University of Saskatchewan. Female Fisher 344 rats (6 -8 weeks old) were obtained from Charles River Laboratory (Montreal, Quebec, Canada). All animals were maintained in our animal facility at the Saskatoon Cancer Center.
Construction of expression vectors and recombinant adenoviruses
The mammalian expression vector pCIneo-H-2K b was constructed by insertion of the H-2K b gene 7 into the EcoRI site of the pCIneo plasmid containing the neo gene for G418 selection (Promega, Madison, Wis). The recombinant human adenoviral vector pLpA-H-2K b was constructed by insertion of the H-2K b gene into the EcoRI site of the adenoviral vector pLpA. 23 The pLpA-H-2K b vector was cotransfected with another plasmid, pJM17, 23 into the 293 cell line using a kit (Calcium Phosphate Transfection System) obtained from Life Technologies (Burlington, Ontario, Canada). Clones of recombinant human adenovirus AdV-H-2K b with the E1 deletion were obtained by limiting dilution analysis of the ability of media to induce a cytopathic effect on fresh 293 cells. In this study, another E1-deleted recombinant human adenovirus, AdV5LacZ, 23 containing the Escherichia coli ␤-galactosidase (␤-gal) marker gene under the transcriptional control of the human cytomegalovirus promoter, was used as a marker as well as a control adenovirus. Viral seed stocks were then obtained by amplification of adenoviruses in 293 cells. Working stocks of the virus were obtained by harvesting 293 cells at 24 hours after infection with the appropriate seed stock. The cell pellets were lysed by three freeze-thaw cycles. Adenoviruses were then purified by two rounds of CsCl ultracentrifugation. Purified virus was mixed with 10% glycerol and dialyzed twice against 500 mL of dialysis buffer containing 10 mM tris(hydroxymethyl)aminomethane (Tris)/HCl (pH 7.5), 1 mM MgCl 2 , and 10% glycerol at 4°C for 6 hours. These purified replication-deficient viruses were aliquoted and stored at Ϫ80°C until use. b , were grown to confluence and harvested using 0.5% trypsin-ethylenediaminetetraacetic acid. A total of 500,000 cells in complete medium from each cell line were plated into each medium culture flask. They were incubated at 37°C for 5 days. The live cells were counted each day after plating using trypan blue (Life Technologies). 6 PFU results in an MOI of 15. Cells were incubated with virus at 37°C in Eagle's minimum essential medium plus 2% FCS for 2 hours. Media containing virus were then removed and replaced with the regular medium. Cells were further incubated at 37°C for 24 hours and analyzed for ␤-gal expression as described previously. 23 Briefly, transfected cells were fixed in PBS containing 37% formaldehyde and 25% glutaraldehyde and stained with 5-bromo b virus was given two more times at 5-day intervals for a total of three injections. As a control, rats were injected i.t. with a single dose of 2.5 ϫ 10 9 PFU of the AdV5LacZ adenovirus. Tumor size was monitored daily using calipers. Rats were sacrificed at 2 weeks after the initial injection of the virus, and tumors were removed and weighed. In all these animal studies, the growth of tumor cells was confirmed by histologic analysis. Student's t test was used for the statistical analysis in these animal studies.
Infection of LN-4 cells in vitro with
Quantitation of cytokine secretion
Rats were sacrificed at 2 weeks after the s. Cocultures were done in quadruplicate, and their supernatants were pooled. Supernatants were collected at 24 hours for IFN-␥ quantitation. For IL-4 quantitation, supernatants were removed at day 4, and the cells were washed and subsequently given fresh media containing 0.1 M concanavalin A. After an additional 24 hours, the supernatants were collected for IL-4 quantitation. All supernatants collected were immediately frozen at Ϫ80°C and measured in batches. Quantitation of secreted cytokines was done in an enzyme-linked immunosorbent assay using the respective Cytoscreen immunoassay kits for IFN-␥ and IL-4 (R&D Systems, Minneapolis, Minn). The results were normalized to known standard curves. 
Chromium release assay
RESULTS
H-2K b expression
Two tumor cell lines, (a) a mouse colonic carcinoma cell line MCA-26 with a haplotype of H-2K d and (b) a rat mammalian carcinoma cell line LN-4, were selected in this study because they are both highly metastatic and poorly immunogenic. As shown in Figure 1 †The mean tumor weight represents the total tumor weight from each group of animal divided by 6. ‡The Student t test showed that the value in this group is significantly different (P Ͻ .01) from that in the control group MCA-26.
§Using the Student t test, the values in these groups were shown not to be significantly different (P Ͼ .5) from that in the control group LN-4.
of xenogeneic origin resulted in a more complete reduction of tumorigenicity in vivo.
Patterns of cytokine production in response to LN-4 and LN-4/H-2K b tumors
The phenotypes of the LN-4-and LN-4/H-2K b -reactive T cells were evaluated by examining the cytokines they secreted in an enzyme-linked immunosorbent assay. As shown in Table 2 
Protective immunity against the parental LN-4 tumor
To examine whether the reduction in tumorigenicity is associated with the induction of protective immunity against the parental LN-4 tumor, six rats that experienced the complete regression of LN-4/H-2K b tumor were immediately rechallenged in a similar fashion with the parental LN-4 tumor cells. As shown in Table 3 , no LN-4 tumor was found in rats that had been immunized previously with LN-4/H-2K b tumor cells. These data indicate that rats inoculated with LN-4/H-2K b tumor cells further developed a protective immune response against the parental LN-4 tumor cells. To study the immune mechanisms involved in this protective immunity, spleen cells from rats that experienced tumor regression were cocultivated in vitro with irradiated LN-4/H-2K b cells. Lymphocytes harvested from these cultures were analyzed for their killing activity in a chromium release assay. As shown in Figure 2A , these lymphocytes displayed significant cytotoxicities to both LN-4/H-2K b and LN-4 tumor cells, with specific killing activities of 68% and 40% at an E:T cell ratio of 100, respectively, but showed no killing activity to an irrelevant rat tumor cell line, LMCR, indicating that the killing activity was LN-4 tumor-specific. As shown in Figure 2B , spleen cells from rats with tumor regression cocultivated with irradiated LN-4 cells also showed cytotoxicity to LN-4 cells, with specific killing activity of 34% at an E:T cell ratio of 100. On the contrary, lymphocytes derived from rats with LN-4 tumor growth showed no lysis of LN-4 tumor cells. ‫ء‬In group 1, there were six rats that experienced tumor regression after inoculation of LN-4/H-2K b cells into their right thighs. At 6 weeks after initial tumor inoculation, each rat in this group was rechallenged in its left thigh with 0.5 ϫ 10 6 LN-4 cells. In the control group, there were six naive rats. Each rat in this group was also challenged in its left thigh with 0.5 ϫ 10 6 LN-4 cells. At 4 weeks after LN-4 tumor inoculation, tumors were removed and weighed.
†The mean tumor weight represents the total tumor weight from each group of rats divided by 6. ‡The Student t test showed that the value in group 1 is significantly different from that in group 2 (P Ͻ .01). One possible explanation is that the tumor-infiltrating lymphocytes are usually inactivated and in a stage of immune suppression although they are present in tumors. 24 The direct and indirect xenogeneic reactions 25, 26 not only induce the destruction of transfected tumor cells expressing the xenogeneic MHC class I but also activate these immune-suppressed tumor-specific tumor-infiltrating lymphocytes in tumors by the local cytokines such as IL-2 secreted from xenoreactive CD4 ϩ T cells. 27 An alternative explanation is that the TAA in the wild-type tumor cannot be presented effectively to the immune system to elicit a strong T-cell response due to its cryptic in nature or the low expression of MHC molecules. As a consequence of the destruction of the transduced tumor cells during the xenogeneic response, the cryptic TAA determinants could be phagocytosed, processed, and more effectively presented by infiltrating macrophages in the xenoreaction 28 and reach a threshold level sufficient to activate CTLs specific for the TAA on parental LN-4 tumor cells. In addition, the xenogeneic reaction can also cause local secretion of cytokines that act through several mechanisms. For example, tumor necrosis factor-␣ and IFN-␥ can be directly toxic to tumor cells. In addition, IFN-␥ can also increase endogenous MHC class I and class II expression, which can present TAA more effectively to lymphocytes. Thus, these local xenoreactions can increase the expression of rat MHC class I gene, and hence enhance the expansion of the anti-MHC class I-TAA CTLs, and in this way lead to the death of the parental LN-4 cells.
Previous studies have demonstrated that the cytokine environment in which T cells are first activated and begin differentiation determines the subsequent cytokine profile of those cells. 29, 30 Therefore, to determine whether the cytokines released by splenic T cells during the in vitro activation step might account for the generation of highly polarized effector T cells, we examined which cytokines were released into culture medium during the in vitro activation step with respective tumor cells. Our data showed that T cells in rats with regression of LN-4/H-2K b tumor secreted IFN-␥, but no IL-4, which is consistent with a Th1-dominant response, whereas T cells in LN-4 tumor-bearing rats secreted IL-4, but no IFN-␥, which is consistent with a Th2-dominant response. Our data are thus consistent with two recent studies reported by others, in which allogeneic tumor cells were used to investigate tumor growth or regression in relation to a Th1 or Th2 immune response. 31, 32 Our results indicate that the poorly immunogenic LN-4 tumor activates a Th2 response, whereas the highly immunogenic LN-4/H-2K b tumor induces a favorable Th1 immune response, leading to complete tumor regression and protective immunity. Our results also raise an important question regarding how to shift a Th2 response in a tumor-bearing host into a Th1 response in favor of tumor regression. A better understanding of the mechanisms by which tumor cells modulate the host immune system may lead to novel approaches to manipulate host-tumor interactions in favor of the development of a protective antitumor immune response.
Adenovirus-mediated gene transfer has been used extensively to deliver various genes into tumor cells for cancer gene therapy. 18 -20 In the present study, rat LN-4 tumor cells were transfected with the recombinant human adenovirus AdV5LacZ. Its infectivity was 74% at an MOI of 1000, which is quite low compared with some human tumor cell lines, where it is 80 -100% at an MOI of 100. 33 In an animal study, we administered an i.t. injection of the adenovirus AdV-H-2K b expressing the xenogeneic H-2K b Ag into LN-4 tumors. Our results showed that the adenovirus-mediated transfer of xenogeneic H-2K b gene was able to significantly inhibit the pre-established LN-4 tumors (six of six) in rats. We assume that it is likely that the tumor inhibition could be greater when applied to human tumors, which are more sensitive to human adenoviral infection. In conclusion, our study shows that the adenovirus-mediated transfer of xenogeneic MHC class I gene may be an effective alternative to the current protocol of cancer gene therapy using allogeneic MHC class I gene transfer. ‫ء‬There were five rats in each group. Each rat was injected s.c. in its right thigh with 0.5 ϫ 10 6 LN-4 cells. At 2 weeks after tumor inoculation, tumors reached 3-4 mm in diameter. In groups 1 and 2, each rat was injected i.t. with 2.5 ϫ 10 9 PFU of the AdV-H-2K b and the AdV5LacZ viruses, respectively. This injection was readministered twice in 5 days for a total of three injections. In the control group, PBS was injected into each tumor. At 2 weeks after the initial vaccination, tumors were removed and weighed. †The mean tumor weight represents the total tumor weight from each group of rats divided by 6. ‡The value in group 1 is significantly different (P Ͻ .01) from that in groups 2 and 3. The value in group 2 is not significantly different (P Ͼ .5) from that in group 3 (Student's t test).
